The averages in clinical trials run by the drugs manufacturer were: Wegovy (injection): 15% weight loss in 68 weeks Wegovy (pill): 14% weight loss in 64 weeks Ozempic: 7% weight loss in 30 weeks Rybelsus: 4% weight loss in 6 months These statistics are from clinical trials, where the research team controls many of the variables
GLP-1s in Action: Ros Scientific Approach GLP-1s play a crucial role in Ros weight loss program
No entanto, no protocolo registrado para o NA-931 , aparece justamente um critrio de excluso tpico desse tipo de droga: excluso de pacientes com histrico de reao a anticorpos monoclonais Esse detalhe chama ateno porque, at aqui, a prpria empresa j descreveu o NA-931 de formas diferentes: nos press releases , como pequena molcula oral no ClinicalTrials , como peptdeo e agora, no desenho desse novo estudo, aparecem critrios tpicos de anticorpos monoclonais Ou seja, ao longo dos documentos, a mesma substncia parece assumir trs naturezas completamente diferentes: pequena molcula peptdeo anticorpo monoclonal Esse tipo de inconsistncia refora a impresso observada nos registros anteriores: partes do protocolo parecem ter sido copiadas de estudos de outras molculas , sem que os critrios fossem completamente revisados para o novo composto
[DOI] [PubMed] [Google Scholar] 32.Scott K.M., et al
GIP activation appears to complement GLP-1 effects synergistically rather than additively, which explains why Tirzepatide (dual agonist) produces significantly more weight loss than Semaglutide (single agonist) despite both activating GLP-1
Some people also report mild fatigue or low energy as their body adjusts, especially if appetite changes lead to smaller meals
